NASDAQ:AGIO - Agios Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $68.00
  • Forecasted Upside: 52.23 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$44.67
▼ -0.99 (-2.17%)
1 month | 3 months | 12 months
Get New Agios Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGIO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$68.00
▲ +52.23% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Agios Pharmaceuticals in the last 3 months. The average price target is $68.00, with a high forecast of $82.00 and a low forecast of $49.00. The average price target represents a 52.23% upside from the last price of $44.67.
Buy
The current consensus among 12 polled investment analysts is to buy stock in Agios Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/9/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/31/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2020

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020BarclaysBoost Price TargetOverweight$46.00 ➝ $50.00High
i
11/19/2020Cantor FitzgeraldBoost Price TargetOverweight$68.00 ➝ $79.00High
i
10/22/2020BarclaysUpgradeEqual Weight ➝ Overweight$46.00High
i
10/19/2020Needham & Company LLCLower Price TargetBuy$71.00 ➝ $69.00Low
i
Rating by Chad Messer at Needham & Company LLC
10/19/2020SVB LeerinkLower Price TargetPositive ➝ Outperform$72.00 ➝ $67.00Medium
i
10/19/2020Piper SandlerLower Price TargetOverweight$80.00 ➝ $73.00Medium
i
10/19/2020Canaccord GenuityReiterated RatingBuy$72.00 ➝ $70.00Medium
i
7/31/2020Cantor FitzgeraldBoost Price TargetOverweight$70.00 ➝ $72.00High
i
Rating by Alethia Young at Cantor Fitzgerald
7/31/2020Canaccord GenuityReiterated RatingBuy$72.00High
i
7/30/2020Needham & Company LLCInitiated CoverageBuy$71.00High
i
Rating by Chad Messer at Needham & Company LLC
6/15/2020SVB LeerinkBoost Price TargetOutperform$70.00 ➝ $72.00Medium
i
6/15/2020GuggenheimBoost Price TargetBuy$60.00 ➝ $66.00Medium
i
6/15/2020CitigroupBoost Price TargetBuy$64.00 ➝ $75.00Medium
i
6/15/2020OppenheimerReiterated RatingHoldMedium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
6/12/2020Piper SandlerBoost Price TargetOverweight$70.00 ➝ $80.00High
i
5/4/2020JPMorgan Chase & Co.Boost Price TargetOverweight$72.00 ➝ $82.00High
i
Rating by Anupam Rama at JPMorgan Chase & Co.
5/1/2020Canaccord GenuityReiterated RatingBuy$72.00High
i
4/30/2020OppenheimerReiterated RatingHoldHigh
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
4/30/2020Needham & Company LLCReiterated RatingBuy$71.00Low
i
3/4/2020BarclaysInitiated CoverageEqual Weight$50.00High
i
3/4/2020CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
2/17/2020Needham & Company LLCReiterated RatingBuy$71.00High
i
2/14/2020Cantor FitzgeraldReiterated RatingOverweight$64.00 ➝ $70.00High
i
Rating by A. Young at Cantor Fitzgerald
2/13/2020CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
2/13/2020OppenheimerReiterated RatingHoldHigh
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/31/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
Rating by Anupam Rama at JPMorgan Chase & Co.
1/21/2020OppenheimerReiterated RatingHoldLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/14/2020CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
12/10/2019CowenReiterated RatingBuyLow
i
Rating by Chris Shibutani at Cowen Inc
12/9/2019BMO Capital MarketsBoost Price TargetOutperform$45.00 ➝ $49.00High
i
12/4/2019JPMorgan Chase & Co.Lower Price TargetOverweight$80.00 ➝ $68.00High
i
11/26/2019Cantor FitzgeraldInitiated CoverageOverweight$64.00Medium
i
Rating by A. Young at Cantor Fitzgerald
11/5/2019CitigroupLower Price TargetBuy$80.00 ➝ $64.00High
i
11/1/2019Royal Bank of CanadaSet Price TargetBuy$79.00N/A
i
Rating by Kennen MacKay at Royal Bank of Canada
10/31/2019Needham & Company LLCReiterated RatingBuy$71.00High
i
10/28/2019Piper Jaffray CompaniesLower Price TargetOverweight$80.00 ➝ $70.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
10/1/2019Royal Bank of CanadaLower Price TargetOutperform$82.00High
i
Rating by Kennen MacKay at Royal Bank of Canada
9/30/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
9/24/2019Piper Jaffray CompaniesSet Price TargetBuy$80.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
9/23/2019GuggenheimUpgradeNeutral ➝ Buy$55.00Low
i
9/12/2019BMO Capital MarketsInitiated CoverageOutperform$45.00Low
i
8/2/2019Royal Bank of CanadaSet Price TargetBuy$89.00Medium
i
Rating by Kennen MacKay at Royal Bank of Canada
5/31/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
5/23/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$55.00Medium
i
5/16/2019Royal Bank of CanadaBoost Price Target$90.00High
i
5/16/2019CowenReiterated RatingBuyHigh
i
5/3/2019Piper Jaffray CompaniesLower Price TargetOverweight$100.00 ➝ $85.00High
i
3/13/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
2/20/2019OppenheimerReiterated RatingMarket PerformLow
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
2/15/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$80.00High
i
Rating by A. Berens at SVB Leerink LLC
2/14/2019Piper Jaffray CompaniesLower Price TargetOverweight$100.00High
i
11/16/2018OppenheimerReiterated RatingHoldLow
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/2/2018CowenReiterated RatingBuyMedium
i
Rating by Chris Shibutani at Cowen Inc
11/1/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
9/24/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$80.00Low
i
Rating by A. Berens at SVB Leerink LLC
9/17/2018GuggenheimInitiated CoverageNeutralLow
i
9/5/2018Canaccord GenuityReiterated RatingBuy$90.00High
i
8/2/2018Needham & Company LLCReiterated RatingBuyHigh
i
8/2/2018Canaccord GenuityReiterated RatingBuyHigh
i
8/2/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
7/23/2018SunTrust BanksReiterated RatingBuy$123.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
6/4/2018Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by Tyler Van Buren at Piper Jaffray Companies
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweight$125.00High
i
5/23/2018CitigroupInitiated CoverageBuy$117.00High
i
5/7/2018Credit Suisse GroupSet Price TargetBuy$95.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/7/2018SunTrust BanksSet Price TargetBuy ➝ Buy$115.00Medium
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
4/11/2018Credit Suisse GroupSet Price TargetOutperform ➝ Buy$80.00 ➝ $95.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
2/15/2018SunTrust BanksReiterated RatingBuy ➝ Buy$80.00 ➝ $101.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
2/15/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$76.00 ➝ $85.00Low
i
2/15/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $80.00Low
i
2/15/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$72.00 ➝ $86.00Low
i
2/14/2018OppenheimerDowngradeOutperform ➝ Market PerformLow
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
2/14/2018UBS GroupDowngradeOutperform ➝ Market PerformLow
i
1/18/2018Royal Bank of CanadaBoost Price TargetOutperform$91.00Medium
i
1/1/2018OppenheimerSet Price TargetBuy$83.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/26/2017OppenheimerSet Price TargetBuy$83.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/12/2017Canaccord GenuitySet Price TargetBuy$90.00High
i
Rating by John Newman at Canaccord Genuity
12/11/2017OppenheimerReiterated RatingBuy$83.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/19/2017SunTrust BanksSet Price TargetBuy$80.00N/A
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
11/17/2017OppenheimerSet Price TargetBuy$83.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/2/2017Credit Suisse GroupBoost Price TargetOutperform$61.00 ➝ $66.00N/A
i
10/4/2017SunTrust BanksReiterated RatingBuy$80.00N/A
i
9/18/2017JPMorgan Chase & Co.Reiterated RatingBuy$76.00Low
i
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$78.00High
i
8/10/2017OppenheimerReiterated RatingOutperform$75.00 ➝ $83.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
8/10/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$54.00 ➝ $72.00Medium
i
8/8/2017Canaccord GenuitySet Price TargetBuy$90.00Low
i
Rating by John Newman at Canaccord Genuity
8/8/2017SunTrust BanksReiterated RatingBuy ➝ Buy$68.00 ➝ $80.00Low
i
8/2/2017Canaccord GenuitySet Price TargetBuy$90.00Medium
i
Rating by John Newman at Canaccord Genuity
8/2/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$50.00 ➝ $80.00High
i
Rating by M. Schmidt at SVB Leerink LLC
8/1/2017Janney Montgomery ScottReiterated RatingHoldHigh
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
6/26/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
6/11/2017OppenheimerSet Price TargetBuy$75.00Medium
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
6/1/2017OppenheimerSet Price TargetBuy$75.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
5/18/2017Canaccord GenuitySet Price TargetBuy$90.00Medium
i
Rating by John Newman at Canaccord Genuity
5/4/2017Canaccord GenuitySet Price TargetBuy$90.00High
i
Rating by John Newman at Canaccord Genuity
4/18/2017Credit Suisse GroupReiterated RatingOutperform$61.00High
i
3/1/2017OppenheimerSet Price TargetBuy$75.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
2/16/2017Canaccord GenuitySet Price TargetBuy$90.00N/A
i
Rating by John Newman at Canaccord Genuity
2/16/2017OppenheimerSet Price TargetBuy$75.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
2/16/2017CowenReiterated RatingBuyN/A
i
2/16/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$57.00N/A
i
1/17/2017CIBCUpgradeMarket Perform ➝ OutperformN/A
i
1/17/2017OppenheimerUpgradeMarket Perform ➝ Outperform$75.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
1/9/2017CowenReiterated RatingBuyN/A
i
1/9/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
1/3/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/19/2016SVB LeerinkReiterated RatingMarket Perform$56.00 ➝ $45.00N/A
i
Rating by M. Schmidt at SVB Leerink LLC
12/18/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/18/2016Canaccord GenuitySet Price TargetBuy$90.00N/A
i
Rating by John Newman at Canaccord Genuity
12/16/2016Needham & Company LLCReiterated RatingBuy$60.00 ➝ $54.00N/A
i
Rating by Chad Messer at Needham & Company LLC
12/7/2016Needham & Company LLCReiterated RatingBuy$60.00N/A
i
Rating by Chad Messer at Needham & Company LLC
12/5/2016Canaccord GenuityReiterated RatingBuy$90.00N/A
i
Rating by john newman at Canaccord Genuity
11/29/2016OppenheimerInitiated CoverageMarket PerformN/A
i
11/21/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
11/4/2016SVB LeerinkReiterated RatingMarket PerformN/A
i
Rating by M. Schmidt at SVB Leerink LLC
11/3/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
10/24/2016Needham & Company LLCInitiated CoverageBuy$60.00N/A
i
9/8/2016Canaccord GenuityReiterated RatingBuy$90.00N/A
i
Rating by John Newman at Canaccord Genuity
8/19/2016BTIG ResearchInitiated CoverageNeutralN/A
i
8/10/2016The Goldman Sachs GroupReiterated RatingNeutral$46.00N/A
i
Rating by Terence Flynn at The Goldman Sachs Group, Inc.
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
6/13/2016The Goldman Sachs GroupReiterated RatingHold$46.00N/A
i
Rating by Terence Flynn at The Goldman Sachs Group, Inc.
6/13/2016Janney Montgomery ScottReiterated RatingNeutral$52.00 ➝ $47.00N/A
i
6/13/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$50.00 ➝ $62.00N/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
6/13/2016Canaccord GenuityUpgradeHold ➝ Buy$50.00 ➝ $90.00N/A
i
Rating by John Newman at Canaccord Genuity
6/10/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$50.00 ➝ $62.00N/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
6/9/2016Canaccord GenuityReiterated RatingHold$50.00N/A
i
Rating by John Newman at Canaccord Genuity
5/24/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
5/19/2016SVB LeerinkReiterated RatingMarket Perform$56.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
5/18/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
5/18/2016Canaccord GenuityReiterated RatingHold$50.00N/A
i
Rating by John Newman at Canaccord Genuity
5/18/2016Credit Suisse GroupBoost Price TargetOutperform$65.00 ➝ $70.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/18/2016SunTrust BanksBoost Price TargetBuy$57.00 ➝ $65.00N/A
i
4/25/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
3/31/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
3/29/2016SunTrust BanksInitiated CoverageBuy$57.00N/A
i
3/27/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
3/4/2016Canaccord GenuityReiterated RatingHold$70.00 ➝ $50.00N/A
i
Rating by John Newman at Canaccord Genuity
3/1/2016Janney Montgomery ScottInitiated CoverageNeutral$43.00N/A
i
2/22/2016The Goldman Sachs GroupLower Price Target$72.00 ➝ $47.00N/A
i
2/19/2016SVB LeerinkReiterated RatingMarket Perform$62.00 ➝ $56.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
2/19/2016Credit Suisse GroupLower Price Target$75.00 ➝ $66.00N/A
i
Rating by Initiated, Yesterday Buy at Credit Suisse Group AG
1/20/2016Credit Suisse GroupInitiated CoverageOutperform$75.00N/A
i
12/7/2015SVB LeerinkDowngradeOutperform ➝ Market Perform$105.00 ➝ $62.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
(Data available from 11/30/2015 forward)
Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $44.67
$43.91
$45.82

50 Day Range

MA: $39.45
$35.16
$45.66

52 Week Range

Now: $44.67
$27.77
$56.74

Volume

197,000 shs

Average Volume

685,156 shs

Market Capitalization

$3.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85